Over the years we have helped our clients answer a wide range of research questions, and we offer a number services and products to help develop, analyze and communicate evidence of value. Below are some of the of the most commonly asked questions that we have answered for our clients. Click on each question for a few examples of relevant Evidera publications, white papers, webinars and research posters. This is just a sampling; see our Publications and More page for more examples or contact us at firstname.lastname@example.org.
Do I understand how my product is being used?
Treatment Selection and Experience in Multiple Sclerosis: Survey of Neurologists. Patient Prefer Adherence. 2014 Apr 3; 8:415-422. eCollection 2014.
Author(s)/Presenter(s): Hanson KA, Agashivala N, Wyrwich KW, Raimundo K, Kim E, Brandes DW
Application of Randomized Clinical Trial Data to Actual Practice: Apixaban Therapy for Reduction of Stroke Risk in Non-valvular Atrial Fibrillation Patients. Curr Med Res Opin. 2013 Oct; 29(10):1253-1261. [Epub 2013 Jul 18]
Author(s)/Presenter(s): Amin A, Stokes M, Wu N, Gatt E, Makenbaeva D, Wiederkehr D, Boulanger L
How can I collect real-world data to support my product’s value?
Estimated Medical Cost Reductions Associated with Use of Novel Oral Anticoagulants vs. Warfarin in a Real-world Non-valvular Atrial Fibrillation Patient Population. J Med Econ. 2014 Nov; 17(11):771-81. [Epub 2014 Aug 26]
Author(s)/Presenter(s): Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH
Effect of General Symptom Level, Specific Adverse Events, Treatment Patterns & Patient Characteristics on Health-related QoL in Patients with Multiple Myeloma: Results of a European, Multicenter Cohort Study. Support Care Cancer. 2014 Feb; 22(2):417-26.
Author(s)/Presenter(s): Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters S, Davies FE
Important Cookie Information - this message will only appear once